Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors

被引:17
|
作者
Harvey, B. D. [1 ]
Siok, C. J. [1 ]
Kiss, T. [1 ]
Volfson, D. [2 ]
Grimwood, S. [1 ]
Shaffer, C. L. [3 ]
Hajos, M. [1 ]
机构
[1] Pfizer Inc, Pfizer Global Res & Dev, Groton Labs, Neurosci Res Unit, Groton, CT 06340 USA
[2] Pfizer Inc, Pfizer Global Res & Dev, Groton Labs, Res Stat, Groton, CT 06340 USA
[3] Pfizer Inc, Pfizer Global Res & Dev, Groton Labs, Dept Pharmacokinet Pharmacodynam & Metab, Groton, CT 06340 USA
关键词
Polysomnography; Quantitative electroencephalography; mGluR5; Rat; Anxiety; HIPPOCAMPAL THETA-RHYTHM; ALLOSTERIC MODULATORS; SLEEP; RAT; EEG; ANTAGONIST; BEHAVIOR; C-11-ABP688; PREGABALIN; COGNITION;
D O I
10.1016/j.neuropharm.2013.06.020
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The Group I metabotropic glutamate receptor subtype 5 (mGluR5) is widely distributed in the brain with dense expression in the cerebral cortex, hippocampus, and basal ganglia. These receptors have been implicated in psychiatric and neurological disorders such as schizophrenia, Fragile X syndrome, addiction, anxiety/depression, Parkinson's disease and neuropathic pain. The present study evaluated the effects of the mGluR5 negative allosteric modulators (NAMs) 4-difluoromethoxy-3-(pyridine-2-ylethynyl)phenyl)5H-pyrrolo[3,4-b]pyridine-6(7H)-yl methanone (GRN-529) and methyl (3aR,4S,7aR)-4-hydroxy-4-[(3-methylphenyl)ethynyl]octahydro-1H-indole-1-carboxylate (AFQ056) on polysomnographic (PSG) and quantitative electroencephalographic (qEEG) measures in freely moving rats. Furthermore, the anxiolytic profile of GRN-529 was characterized in anesthetized rats by measuring stimulation-induced hippocampal theta oscillation. The present findings demonstrate that inhibition of mGluR5 via its allosteric site profoundly modulates high-level neuronal network activities as indicated by changes in sleep-wake activity and power distribution of qEEG. Both GRN-529 and AFQ056 reduced the total time spent in rapid-eye movement with AFQ056 producing a significant increase in wakefulness at the highest dose tested. Additionally, qEEG revealed significant compound-induced increases in delta power concomitant with more subtle decreases in theta and alpha band power. Receptor occupancy (RO) studies revealed that GRN-529 and AFQ056 at all doses resulted in over 45% mGluR5 occupancy. Furthermore, GRN-529 dose-dependently decreased elicited hippocampal theta frequency, consistent with previous findings using clinically active anxiolytic compounds. The described changes in neurophysiological signals identified in freely moving rats may be considered suitable translational biomarkers for the clinical evaluation of mGluR5 NAMs. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:19 / 30
页数:12
相关论文
共 50 条
  • [2] Dynamics and modulation of metabotropic glutamate receptors
    Rondard, Philippe
    Pin, Jean-Philippe
    CURRENT OPINION IN PHARMACOLOGY, 2015, 20 : 95 - 101
  • [3] Involvement of group III metabotropic glutamate receptors in the modulation of spinal nociceptive signals
    Yang, Xiaorong
    Zhang, Yu
    Zhao, Xin
    Liu, Naihong
    Qiao, Jiantian
    Zhang, Ce
    NEURAL REGENERATION RESEARCH, 2009, 4 (06) : 443 - 448
  • [4] MODULATION OF GLUTAMATE EXOCYTOSIS BY PRESYNAPTIC METABOTROPIC GLUTAMATE RECEPTORS
    SANCHEZPRIETO, J
    HERRERO, I
    VAZQUEZ, E
    JOURNAL OF NEUROCHEMISTRY, 1994, 63 : S1 - S1
  • [5] Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential
    Gregory, Karen J.
    Dong, Elizabeth N.
    Meiler, Jens
    Conn, P. Jeffrey
    NEUROPHARMACOLOGY, 2011, 60 (01) : 66 - 81
  • [6] Modulation of the Basal Ganglia by Metabotropic Glutamate Receptors: Potential for Novel Therapeutics
    Marino, Michael J.
    Conn, P. Jeffrey
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2002, 1 (03) : 239 - 250
  • [7] Allosteric modulation of metabotropic glutamate receptors.
    Johnson, MP
    Jagdmann, GE
    Britton, TC
    Barda, DA
    Hornback, WJ
    Dressman, BA
    Johnson, KW
    Kingston, AE
    Nisenbaum, ES
    Owton, WM
    Baker, SR
    Zia-Ebrahimi, M
    Tizzano, JP
    Monn, JA
    Schoepp, DD
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U230 - U230
  • [8] Metabotropic glutamate receptors, 5 years on
    Collingridge, Graham L.
    Manahan-Vaughan, Denise
    Nicoletti, Ferdinando
    Schoepp, Darryle D.
    NEUROPHARMACOLOGY, 2017, 115 : 1 - 3
  • [9] Modulation of metabotropic glutamate receptors as potential treatment for acute and chronic neurodegenerative disorders
    Lea, PM
    Faden, AI
    DRUG NEWS & PERSPECTIVES, 2003, 16 (08) : 513 - 522
  • [10] Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential
    Kew, JNC
    PHARMACOLOGY & THERAPEUTICS, 2004, 104 (03) : 233 - 244